EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus

Avneesh Shrivastava, Gunavanthi D Boorgula, Sanjay Singh iD, Danaleigh Stiles, Pamela J McShane iD, Megan Devine iD, Tawanda Gumbo iD, Shashikant Srivastava iD

Microbiology Spectrum · 07.10.2025 · 13 (10)

DOI: 10.1128/spectrum.01492-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 07.10.2025. Verfasst von Avneesh Shrivastava und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Mycobacterium abscessus, Cephalosporins, Carbapenems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Cystic Fibrosis Foundation Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the long therapy duration, the treatment outcomes for Mycobacterium abscessus lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase enzymes. Therefore, β-lactamase inhibitors have been developed to overcome this problem. Here, we performed minimum inhibitory concentration studies with a reference MAB strain (ATCC19977) and a collection of 63 clinical isolates for penicillin, cephalosporin, and carbapenems alone or in combination with β-lactamase inhibitors, sulbactam/durlobactam (Sul/Dur). There was an average 64-fold (range: 19 to 103) reduction in drugs MIC in the presence of 4 mg/L Sul/Dur (1:1 ratio). The fold reduction in MICs was as follows: amoxicillin 94, ceftriaxone 103, cefuroxime 69, cefdinir 19, cefalexin 74, imipenem 23, meropenem 37, tebipenem 89, and faropenem 74. The Sul/Dur combination also improved the kill effect of the tested β-lactams by multiple folds as follows: amoxicillin 12.6, ceftriaxone 2,872, cefuroxime 135.5, cefdinir 26.5, cefalexin 1,030, imipenem and meropenem 14, and faropenem 5.5. Since imipenem is already included in the MAB-LD treatment recommendations and ceftriaxone achieves very high lung concentration, we propose to first test these drugs with Sul/Dur as a double β-lactam-β-lactamase backbone regimen to advance the therapy for MAB-LD. IMPORTANCE β-Lactams are among the recommended drugs for the treatment of Mycobacterium abscessus lung disease (MAB-LD); however, they are prone to hydrolysis by MAB β-lactamase enzymes. We show that sulbactam/durlobactam (Sul/Dur) can improve the kill effect of several β-lactam antibiotics that, otherwise, due to observed high minimum inhibitory concentration, deem ineffective. Based on our findings, we propose imipenem that is already included in the MAB-LD treatment recommendations and ceftriaxone that achieves very high lung concentration, to test with Sul/Dur as a double β-lactam-β-lactamase backbone regimen to advance the therapy for MAB-LD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsMycobacterium abscessusCephalosporinsCarbapenemsSulbactamAzabicyclo Compoundsbeta-Lactamase InhibitorsMicrobial Sensitivity TestsHumansMycobacterium Infections, NontuberculousDrug Synergism

Stichwörter der Autor:innen

MICcarbapenemscephalosporinsnontuberculous mycobacteria

Substanzen

Anti-Bacterial AgentsCephalosporinsCarbapenemsSulbactamAzabicyclo Compoundsdurlobactambeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
  • Undergraduate Medical Education, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
  • Section of Pulmonary and Critical Care, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
  • IMPI Biotechnology Company Incorporated, Mount Hampden, Zimbabwe.
  • Department of Cellular and Molecular Biology, The University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.

ORCID-Profile: Sanjay Singh, Pamela J McShane, Megan Devine, Tawanda Gumbo, Shashikant Srivastava

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Cystic Fibrosis Foundation Therapeutics

Zitieren

APA

Shrivastava, A., Boorgula, G. D., Singh, S., Stiles, D., McShane, P. J., Devine, M., Gumbo, T., & Srivastava, S. (2025). Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus. Microbiology Spectrum, 13(10). https://doi.org/10.1128/spectrum.01492-25

Vancouver

Shrivastava A, Boorgula GD, Singh S, Stiles D, McShane PJ, Devine M, et al. Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus. Microbiology Spectrum. 2025;13(10). doi:10.1128/spectrum.01492-25

BibTeX
@article{Shrivastava2025,
  author = {Shrivastava, Avneesh and Boorgula, Gunavanthi D and Singh, Sanjay and Stiles, Danaleigh and McShane, Pamela J and Devine, Megan and Gumbo, Tawanda and Srivastava, Shashikant},
  title = {Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {10},
  doi = {10.1128/spectrum.01492-25}
}
Kostenlos starten →